Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial

Lancet

Volumn 359, Issue 9323, 2002, Pages 2065-2071

  Schmitz, Norbert ^a,m   Pfistner, Beate ^b   Sextro, Michael ^b   Sieber, Markus ^b   Carella, Angelo M ^c   Haenel, Matthias ^d   Boissevain, Friederike ^e   Zschaber, Reinhart ^f   Müller, Peter ^g   Kirchner, Hartmut ^h   Lohri, Andreas ⁱ   Decker, Susanne ^j   Koch, Bettina ^b   Hasenclever, Dirk ^k   Goldstone, Anthony H ^l   Diehl, Volker ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF GENOA   (Italy)

^d KLINIKUM CHEMNITZ   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g KLINIKUM AUGSBURG   (Germany)

^h Krankenhaus Siloah   (Germany)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j UNIVERSITY OF ROSTOCK   (Germany)

^k UNIVERSITY OF LEIPZIG   (Germany)

^l UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^m DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFECTION; INTERMETHOD COMPARISON; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUROLOGICAL COMPLICATION; PATIENT SELECTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037097044     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08938-9     Document Type: Article

References (30)

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
2. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492
3. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the Germany Hodgkin's Lymphoma Study Group
4. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease
5. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease
6. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group
7. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease
8. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia Experience 1970 to 1988
9. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
10. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
11. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
12. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant
13. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
14. Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF
15. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts
16. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
17. Intensive therapy with cyclophosphamide, carmustine, etoposide 6 cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
18. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
19. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center eight-year study of 155 patients
20. Comparison of high-dose therapy and autologous stem cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study
21. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantationm
22. Second cancers after treatment of Hodgkin's disease
23. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
24. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
25. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
26. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease
27. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
28. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with cytoreduction for the treatment of malignant and non-malignant hematologic diseases
29. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hemopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma